# US 2026/0216315 A1 · Influenza vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216315 A1
- Document ID: US20260216315A1
- Status: Published application
- Kind: A1
- Application number: 19/303,933
- Filed: 2025-08-19
- Published: 2026-07-30
- Earliest claimed: 2016-11-11
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Giuseppe Ciaramella
- Web page: https://patentgrep.com/patent/US20260216315A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

## Claims

### Claim 1

A method of inducing an influenza virus antigen-specific immune response in a human subject, the method comprising administering by intramuscular injection to the human subject a composition comprising 10-100 μg of a messenger ribonucleic acid (mRNA) polynucleotide to thereby induce a protective antigen-specific immune response in the subject, wherein the mRNA polynucleotide comprises an open reading frame encoding an influenza virus hemagglutinin (HA) antigen and is formulated in a lipid nanoparticle (LNP), wherein 100% of uracil nucleosides in the open reading frame are N1-methylpseudouridine, and wherein the LNP comprises a cationic lipid of Formula (I):
or a salt or isomer thereof, wherein:
R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
R4 is —(CH2)nQ, where Q is —OR, and n is independently selected from 1, 2, 3, 4, and 5;
each R5 is H;
each R6 is H;
M and M′ are independently selected from —C(O)O— and —OC(O)—;
R7 is H;
R is H;
R′ is H;
R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl; and
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cationic lipid of Formula (I) is Compound 25:

### Claim 3 (depends on 1)

The method of claim 1, wherein the LNP comprises 20-60 mol % cationic lipid of Formula (I), 5-25 mol % neutral lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neutral lipid is DSPC, the sterol is cholesterol, the PEG-modified lipid is PEG-DMG, and the cationic lipid of Formula (I) is Compound 25:

### Claim 5 (depends on 1)

The method of claim 1, wherein the HA antigen is an H10 HA antigen.

### Claim 6 (depends on 5)

The method of claim 5, wherein the H10 HA antigen comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 4.

### Claim 7 (depends on 5)

The method of claim 5, wherein the H10 HA antigen is an H10N8 HA antigen.

### Claim 8 (depends on 1)

The method of claim 1, wherein the influenza virus antigen-specific immune response comprises a B cell response.

### Claim 9 (depends on 1)

The method of claim 1, wherein the influenza virus antigen-specific immune response comprises a T cell response.

### Claim 10 (depends on 1)

The method of claim 1, comprising administering a booster dose of the composition to the human subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method of inducing an influenza virus antigen-specific immune response involves a single administration of the composition by intramuscular injection, and wherein the protective immune response is induced with the single administration.
